Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.73 |
| ▸ | FLT1 | P17948 | 5/20 | 0.73 |
| ▸ | KIT | P10721 | 3/20 | 0.73 |
| ▸ | CSF1R | P07333 | 2/20 | 0.73 |
| ▸ | ABL1 | P00519 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.73 |
| ▸ | FLT4 | P35916 | 1/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.60 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.55 |
| ▸ | SMO | Q99835 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356168 | 0.84 | KDR (1.00) | KDRFLT1KITCSF1RABL1 | |
| SCHEMBL4976103 | 0.84 | KDR (1.00) | KDRFLT1KITCSF1RABL1 | |
| SCHEMBL427615 | 0.82 | KDR (0.84) | KDRFLT1KITCSF1RABL1 | |
| Hydrochloric Acid SCHEMBL447740 | 0.82 | KDR (0.83) | KDRFLT1KITCSF1RABL1 | |
| SCHEMBL4979871 | 0.80 | KDR (0.77) | KDRFLT1KITCSF1RABL1 | |
| SCHEMBL5964886 | 0.79 | KDR (0.72) | KDRFLT1KITCSF1RABL1 | |
| SCHEMBL427738 | 0.79 | KDR (0.68) | KDRFLT1KITCSF1RABL1 | |
| SCHEMBL4979592 | 0.79 | KDR (0.74) | KDRFLT1KITCSF1RABL1 | |
| SCHEMBL12544169 | 0.77 | RXFP1 (0.88) | RXFP1P2RX1 | |
| SCHEMBL4981385 | 0.76 | KDR (0.68) | KDRFLT1KITCSF1RABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | claimed |
| CN-1152014-C | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | ��˹��ŵ�� | 2004-06-02 | — | — | CN | claimed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | claimed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | claimed |
| CN-1331680-A | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-01-16 | — | — | CN | claimed |
| US-20080085902-A1 | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent | BOLD GUIDO | 2008-04-10 | — | — | US | disclosed |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ | 2006-04-06 | — | — | US | disclosed |
| US-7002022-B2 | N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF | NOVARTIS AG (CH) | 2006-02-21 | — | — | US | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| CN-1152014-C | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | ��˹��ŵ�� | 2004-06-02 | — | — | CN | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-20020187942-A1 | Method for producing beta-D-ribofuranose derivatives or optical isomers thereof | AJINOMOTO CO., INC. (JP) | 2002-12-12 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| CN-1331680-A | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085902-A1 | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent | VEGFA, FLT1, FLT4 | KDR 4/4885FLT1 2/4885KIT 95/4885 |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | KDR 4/4885FLT1 6/4885KIT 1200/4885 |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NR2E3, AXL, FLT1 | KDR 6/4885FLT1 3/4885KIT 1240/4885 |
| US-20020187942-A1 | Method for producing beta-D-ribofuranose derivatives or optical isomers thereof | DERA, RNGTT, DUT | KDR 2680/4885FLT1 2727/4885KIT 4460/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | KDR 3/4885FLT1 6/4885KIT 1055/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | KDR 4/4885FLT1 6/4885KIT 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.